Related Experiment Videos
Matrix metalloproteinase-3 gene polymorphisms are associated with ischemic stroke
Su Kang Kim1, Sung Wook Kang, Dong Hwan Kim
1Kohwang Medical Research Institute, School of Medicine, Kyung Hee University, Seoul, Republic of Korea.
Summary
This study found that specific variations in the MMP3 gene are linked to an increased risk of ischemic stroke (IS) in the Korean population, particularly in women. No association was found for intracerebral hemorrhage (ICH).
Area of Science:
- Genetics
- Neurology
- Cardiovascular Diseases
Background:
- Stroke is a complex disease with diverse causes.
- Identifying genetic risk factors for stroke subtypes is crucial.
- Matrix metalloproteinases (MMPs) play a role in post-stroke processes.
Purpose of the Study:
- To investigate the association between MMP3 gene single nucleotide polymorphisms (SNPs) and stroke risk in Koreans.
- To differentiate the genetic contribution of MMP3 in ischemic stroke (IS) versus intracerebral hemorrhage (ICH).
Main Methods:
- Genotyping of three MMP3 SNPs (rs520540, rs602128, rs679620) in 186 stroke patients and 668 controls.
- Statistical analysis using logistic regression models and Bonferroni correction.
- Haplotype analysis to assess combined SNP effects.
Main Results:
- Three MMP3 SNPs were significantly associated with IS, but not ICH.
- The association with IS was particularly notable in the female subgroup.
- Bonferroni correction confirmed the statistical significance of these findings for IS.
Conclusions:
- The MMP3 gene is associated with the development of ischemic stroke in the Korean population.
- MMP3 gene variations do not appear to be associated with intracerebral hemorrhage risk.
- Further research may elucidate the specific mechanisms linking MMP3 to IS pathogenesis.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...